Streetbeat News

Products Services

LLY

Eli Lilly's tirzepatide, initially known for weight loss, has shown effectiveness in treating obstructive sleep apnea (OSA) in late-stage SURMOUNT-OSA phase 3 trials. The drug significantly reduced the apnea-hypopnea index (AHI) compared to placebo, meeting primary endpoints. It also led to substantial body weight reduction. Lilly plans to submit these findings to the FDA and other global regulatory bodies. Following this news, LLY shares rose 2.58% in premarket trading.

Portfolio Pulse from Vandana Singh

April 17, 2024 | 12:59 pm

PXMD

PaxMedica (PXMD) shares surged following an emergency request from the Ministry of Health of Malawi for access to IV suramin, indicating strong international interest in the company's product.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:59 pm

MCHI

Chinese exporters at the Canton Fair are facing challenges despite China's 5.3% economic growth in Q1, including a decline in exports and producer prices. Increased economic and political tensions with the U.S., global trade slowdowns, and manufacturing overcapacity are key issues. Some sectors, like high-tech, remain optimistic due to government support. Trade tensions could worsen with potential U.S. tariffs and blacklisting of Chinese companies. The iShares MSCI China ETF (MCHI) saw a 1.02% dip.

Portfolio Pulse from Benzinga Neuro

April 17, 2024 | 12:58 pm

PLTR

Palantir Technologies Inc. (NYSE:PLTR) shares are trading higher in the premarket session after the company announced it has been designated as an 'Awardable' vendor for the Chief Digital and Artificial Intelligence Office's (CDAO) Tradewinds Solutions Marketplace. This designation allows the Department of Defense to access two of Palantir's product offerings, including its AI Mission Command Capability and Predictive Maintenance & Precision Sustainment Suite, through the Marketplace to support critical missions.

Portfolio Pulse from Nabaparna Bhattacharya

April 17, 2024 | 12:52 pm

PTIX

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) announced that COO Dr. Andrew Slee will present on their drug candidate PT00114 at the Peptide Based Therapeutic Summit in Boston on April 23, 2024. The presentation will highlight PT00114's ability to cross the blood-brain barrier, offering potential in neuro-psychiatric treatment. Preclinical data and ongoing clinical safety trial insights will be shared, emphasizing the drug's innovative approach and efficacy.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:47 pm

SRM

SRM Entertainment, Inc. (NASDAQ:SRM) announced receiving an order for over 36,000 Misting Fans, valued at approximately $900,000, from a longstanding Orlando theme park customer. These custom-designed fans, popular among theme park visitors for staying cool, are set to be delivered in time for the summer season.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:43 pm

LLY

Eli Lilly's stock is trading higher following positive results from Phase 3 clinical trials of tirzepatide injection, which showed a reduction in the apnea-hypopnea index compared to a placebo.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:41 pm

NRXP

NRx Pharmaceuticals released data indicating that in rodent models, their drug NRX-101 showed no impact on gut or vaginal flora. This finding is significant for the drug's safety profile, as it suggests that NRX-101 does not disrupt the microbiome, a common concern for new medications.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:35 pm

IGMS

SNY

IGM Biosciences has entered into a global collaboration agreement with Sanofi to create and develop IgM agonist antibodies, focusing exclusively on immunology and inflammation targets. This partnership aims to leverage the expertise of both companies in the field of immunology to address unmet medical needs.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:34 pm

SVMH

SRIVARU has successfully completed AIS 156 testing and certification for its Lithium Iron Phosphate (LFP) battery pack, marking a significant milestone in the company's development of battery technology.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:31 pm